Research programme: Parkinson's disease therapeutics - MRC Technology/Yabao Pharmaceutical Group
Latest Information Update: 25 Nov 2014
At a glance
- Originator MRC Technology
- Developer MRC Technology; Yabao Pharmaceutical Group
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Research Parkinson's disease
Most Recent Events
- 21 Nov 2014 Early research in Parkinson's disease in China and the United Kingdom (unspecified route)